作者: Luis A. Fernández-Morales , Miquel A. Seguí , Xavier Andreu , Elsa Dalmau , Amparo Sáez
关键词: Trastuzumab 、 Estrogen receptor 、 Locally advanced 、 Breast cancer 、 Oncology 、 Internal medicine 、 Disease 、 Progesterone receptor 、 Hormone receptor 、 In patient 、 Medicine
摘要: Abstract Purpose In clinical practice, it is possible to classify breast tumors according estrogen receptor (ER), progesterone (PgR), and HER2 overexpression: ER negative, PgR overexpressing; negative; positive, the less frequent remaining 4 combinations. The aim of this study was determine percentage pathologic complete response (pCR) in patients with locally advanced cancer (LABC) treated neoadjuvant or primary chemotherapy anthracyclines taxanes grouped ER, PgR, status. Patients Methods LABC including were status; pCR rates analyzed using χ 2 test; correlations a P value ≤ 0.05 considered statistically significant. Results A total 103 treated. Only 100 included for analysis pCR. Eighteen exhibited rate each subgroup as follows: 39.1% (9 23) had ER-negative, PgR-negative, HER2-negative disease ( Conclusion LABC, grouping status can help predict chemotherapy.